Kenya Receives First AIDS Treatment: Lenacapavir Shipment | RezoNórdwest
- Kenya has taken a significant step forward in its HIV prevention efforts with the arrival of its first shipment of February 17, 2026, of lenacapavir, a long-acting injectable...
- Lenacapavir represents a new class of HIV prevention medication.
- The initial shipment consists of February 17, 2026, 21,000 starter doses, delivered in partnership with the Global Fund and sourced from the United States.
Kenya has taken a significant step forward in its HIV prevention efforts with the arrival of its first shipment of , of lenacapavir, a long-acting injectable pre-exposure prophylaxis (PrEP). This new approach to HIV prevention offers a potential alternative to daily oral PrEP and health officials believe it could substantially impact new infection rates.
What is Lenacapavir and How Does it Work?
Lenacapavir represents a new class of HIV prevention medication. Unlike daily oral PrEP, which requires consistent adherence, lenacapavir is administered as an injection, initially as a starter dose, followed by continuation doses. This less frequent dosing schedule – administered twice a year – aims to improve adherence and provide sustained protection against HIV acquisition. The medication works by interfering with the virus’s ability to attach to cells, preventing it from establishing an infection.
The Shipment and Rollout Plan
The initial shipment consists of , 21,000 starter doses, delivered in partnership with the Global Fund and sourced from the United States. An additional 12,000 continuation doses are expected by , to support patients who have initiated treatment. A further 25,000 doses are planned to be shipped from the U.S. Government to bolster early implementation. The rollout will be implemented by the National AIDS and STI Control Programme (NASCOP).
The national rollout will be phased, beginning in . The first phase will focus on 15 counties identified as having a high burden of HIV infections. Subsequent phases will progressively expand coverage nationwide, prioritizing service preparedness, reliable medication supply, and sustainable scaling of the program.
Government Approval and Safety Assessments
The introduction of lenacapavir followed a thorough review process by the Kenyan government. The Pharmacy and Poisons Board completed a scientific evaluation of the drug’s safety, quality, and effectiveness in , and subsequently registered both the oral and injectable formulations for use in Kenya. This decision was informed by prior approvals from the U.S. Food and Drug Administration in , and the World Health Organization (WHO) in .
Director General for Health, Dr. Patrick Amoth, reassured the public regarding the safety of the vaccine, emphasizing the rigorous review process undertaken before its approval. He stated that the government is committed to innovative, people-centered approaches to ending the HIV epidemic.
Cost and Accessibility
The estimated cost of the lenacapavir vaccine is approximately Ksh 7,800 per patient, which the government considers relatively cheaper than previous prevention options. While the specific funding mechanisms and accessibility details for the broader population haven’t been fully outlined, the government’s commitment to a phased rollout suggests a focus on reaching those most at risk.
Implications for HIV Prevention in Kenya
Kenya has been actively working to reduce new HIV infections. The introduction of lenacapavir represents a significant addition to the country’s HIV prevention toolkit, which already includes oral PrEP, condom promotion, and voluntary medical male circumcision. The long-acting nature of the injectable PrEP is expected to address challenges related to adherence, a common barrier to the effectiveness of daily oral PrEP.
This development also positions Kenya as a leader in adopting next-generation HIV prevention technologies in the region, with several other African countries preparing to introduce similar interventions. The success of the rollout will likely be closely monitored as a model for other nations facing similar public health challenges.
Looking Ahead
The rollout of lenacapavir is a promising development in the fight against HIV in Kenya. Continued monitoring of its effectiveness, accessibility, and potential side effects will be crucial. The phased implementation approach, coupled with ongoing efforts to strengthen the healthcare system, will be essential to maximizing the impact of this new prevention tool. The Ministry of Health will be guiding the rollout based on epidemiological trends and health-system readiness, ensuring a data-driven and responsive approach to HIV prevention.